Collaboration and licence agreement signed with Bristol-Myers Squibb for lead program Strengthened position in the innate immunity field Total cash increased to €46.6 million from €34.6 million at the...

Revenue of 11.7 million euros including payments from partners Bristol-Myers Squibb and Novo Nordisk A/S as well as research tax credit Strong cash position with 46.6 million euros in cash, cash...

Innate Pharma co-owns intellectual property rights relating to the NKp46 receptor with INSERM, the French National Institute of Health and Medical Research Endorses Innate Pharma’s fruitful...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its tentative financial...

Turnover of 3.1 million euros Cash position as at September 30, 2011 of 49.3 million euros Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class...